Applicant, as named in the Orange Book
Catalyst Pharms
Next listed expiry: Firdapse on 25 Feb 2037. 2 products with live protection, 2 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Firdapse amifampridine phosphate | amifampridine phosphate | 208078 | 25 Feb 2037 | patent |
| Agamree vamorolone | vamorolone | 215239 | 16 Jul 2040 | patent |
Recent events
- 25 Oct 2026Fycompa · Generic approved 25 Nov 2025
- 25 Oct 2026Fycompa · Generic approved 2 Oct 2026
- 25 Oct 2026Fycompa · Generic approved 15 Jun 2026
- 25 Oct 2026Fycompa · Generic approved 25 Nov 2025
Products without listed protection (2)
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Fycompa · 6 strengths perampanel | perampanel | 202834 | open now | no listed protection |
| Fycompa perampanel | perampanel | 208277 | open now | no listed protection |